brachytherapy improves efficiency in thecancer treatment and avoid side effects according to Nucletron.
Sevilla hosts the 2nd Congress of societiesMedical physics and protection radiation.
– thebrachytherapy has fewer side effects than external radiation andIt decreases the risk of later incontinence or dysfunctionErectile.
– inour country, prostate cancer is the second most common tumor between themen after cancer of lung
-NucletronIt shows their latest equipment for exact knowledge of the location,dimension and variations of the tumor during the whole treatment.
Seville, may 2011. – brachytherapyin the treatment of prostate cancer reduces the processing time andIt favours the speedy recovery of the patient. Nucletron, companydevelops innovative Oncology solutions focused to theimprovement of the quality of life of the patient, has been known in Sevilla itsrecent advances in brachytherapy for the treatment of prostate canceron the occasion of the second Congress of the Spanish companies ofMedical physics and radiological protection, from 10 to 13 May.
prostate cancer is cancer morecommon among the European men, while their mortality declines each yearas a result of early diagnosis and therapeutic innovations.
according to the data submitted by Nucletron, thebrachytherapy has the advantage of having fewer side effects than theexternal radiation (EBT). In other words, the risk of laterincontinence and erectile dysfunction is low when this has been usedtechnique. These factors minimize the impact on the quality of life of thepatient, since a shorter treatment received and recovers soon,can continue with its daily activity in a way almost immediately.
the prostate cancer in Spain.
in our country, prostate cancer is thesecond most common tumor among males after lung cancer . according to data from global incidence of cancer in Spain, it is estimated thatby 2015 the incidence of prostate cancer will be approximately 16,000cases.
Furthermore, it is observed that increasingly affects toyounger men, in particular, about 50 years. According to thespecialists, this is probably due to the influence of factorsenvironmental and styles of life, as well as the development of programmes ofscreening in primary care and specialty centers and increasedsocial awareness.
about brachytherapy.
brachytherapy involves the inclusion ofradioactive sources in the patient, is a minimally invasive butthat it offers very good results to radiate the tumor from within. Thebrachytherapy helps health professionals reach a very highprecision when it comes to delivering the doses of radiation, which allows to reducethe risk of tissue and healthy organs surrounding the tumor will bedamaged.
against other types of radiation therapy as theexternal radiation (EBT), brachytherapy releases the necessary dose ofradiation in a smaller time period, the treatment lasts from one to twodays from the seven weeks that can prolong the EBT and accuracy toget brachytherapy reduces the risk of tissue and healthy organssurrounding the tumor will be damaged, at the time that minimize the effectsside and significantly reduce the time of recovery of the patient
the II Congress set of societiesSpanish for medical physics and radiological protection will be held from 10 to 13May 2011 in Seville, with the motto “quality and safety in the use of””radiation”.
according to Eduardo Rodriguez, CEO of Nucletron forthe South of Europe, En Nucletron continueprogress in the research, development and dissemination of brachytherapy,driven by good performance in both directions, both in the improvement ofthe quality of life and patient recovery, as benefits arising interms of cost savings and optimization of resources is this technologyfor hospitals, to reduce the time of application and theaccuracy of the treatment ”.
the new planning system forRadiotherapy, Oncentra ® and some of its applications for the treatment of theprostate cancer and AccuBoost, first technology used treatmentof brachytherapy in way non-invasive for the treatment of breast cancer,These are some of the equipment provided by Nucletron in 2nd CongressSet of Spanish societies of Fïsica medical and protection radiation.
about Nucletron.
Nucletron develops innovative solutions forRadiology Oncology, to improve the effectiveness of treatments and careto the patient. Nucletron is a world leader in brachytherapy. Since its inception, in1975, bet for innovation and the close collaboration with clinical teamsindividual to offer more advanced forms of radiation andefficient, integrated products, software and services.
with headquarters in the Netherlands and offices in 16countries, provides equipment and services to more than 3,000 institutions in 120countries. In Spain, with presence and activity since 1975, brings his equipment to more than 230 centersoncologic.
Nucletron, with 500 employees inin 2010 all over the world, reached a turnover of 130 million Euros.
